Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2020

01-03-2020 | Radiotherapy | Brief Research Article

A new and simple scoring system to predict overall survival after irradiation for metastatic spinal cord compression

Authors: P. Nenclares, S. Guardado, L. Asiáin, M. Á. Pérez-Escutia, M. C. Peña, A. Bartolomé, A. Ruíz, M. Á. Cabeza, M. Colmenero, N. Gascón, V. Rodríguez, R. Prados, R. D´Ambrosi, J. F. Pérez-Regadera

Published in: Clinical and Translational Oncology | Issue 3/2020

Login to get access

Abstract

Purpose

To develop a model that predicts survival in patients irradiated for metastatic spinal cord compression (MSCC), hence assisting in the decision between a short and a long-course radiotherapy (RT) regimen.

Methods

138 patients diagnosed with MSCC and treated with RT alone were included. Based on a multivariate analysis, a scoring system was developed. It included four prognostic variables: age, number of vertebrae, ECOG and histology. Total scores ranged between 14 and 24 points and patients were divided into two groups.

Results

The 6-month survival rate was 22% for patients with a score of 14–18 points; and 69% for patients with a score of 19–24 points (P < 0.001). The system exhibits a high specificity and positive predictive value and an appropriate discriminative ability.

Conclusions

Patients with scores between 19 and 24 points were found to survive longer, thus a long-course RT appears to be more appropriate.
Literature
1.
Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJA, Basic H, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24:3388–93.CrossRef
2.
Rades D, Dunst J, Schild SE. The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer. 2008;112:157–61.CrossRef
3.
Chow E, Harris K, Fung K. Successful validation of a survival prediction model in patients with metastases in the spinal column. Int J Radiat Oncol. 2006;65:1522–7.CrossRef
4.
Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011;34:535–46.CrossRef
5.
Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine. 2001;26:298–306.CrossRef
6.
Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30:2186–91.CrossRef
7.
Bach F, Larsen BH, Rohde K, Børgesen SE, Gjerris F, Bøge-Rasmussen T, et al. Metastatic spinal cord compression occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien). 1990;107:37–433.CrossRef
8.
Helweg-Larsen S, Sørensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys. 2000;46:1163–9.CrossRef
9.
Rose PS, Buchowski JM. Metastatic disease in the thoracic and lumbar spine: evaluation and management. J Am Acad Orthop Surg. 2011;19:37–48.CrossRef
10.
Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet Lond Engl. 2005;366:643–8.CrossRef
11.
McLinton A, Hutchison C. Malignant spinal cord compression: a retrospective audit of clinical practice at a UK regional cancer centre. Br J Cancer. 2006;94:486–91.CrossRef
12.
Rades D, Evers JN, Rudat V, Bajrovic A, Karstens JH, Schild SE. A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. BMC Cancer. 2014;14(14):589.CrossRef
13.
Hadden NJ, McIntosh JRD, Jay S, Whittaker PJ. Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review. Melanoma Res. 2018;28:1–7.CrossRef
14.
West HJ, Jin JO (2015) JAMA oncology patient page. Performance status in patients with cancer. JAMA Oncol. 2015;1:998.CrossRef
15.
Rades D, Veninga T, Bajrovic A, Karstens JH, Schild SE. A validated scoring system to identify long-term survivors after radiotherapy for metastatic spinal cord compression. Strahlenther Onkol Organ Dtsch Röntgenges Al. 2013;189:462–6.CrossRef
16.
Sørensen S, Børgesen SE, Rohde K, Rasmusson B, Bach F, Bøge-Rasmussen T, et al. Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer. 1990;65:1502–8.CrossRef
17.
Constans JP, de Divitiis E, Donzelli R, Spaziante R, Meder JF, Haye C. Spinal metastases with neurological manifestations. Review of 600 cases. J Neurosurg. 1983;59:111–8.CrossRef
18.
Maranzano E, Latini P, Checcaglini F, Ricci S, Panizza BM, Aristei C, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Cancer. 1991;67:1311–7.CrossRef
19.
Stark RJ, Henson RA, Evans SJ. Spinal metastases. A retrospective survey from a general hospital. Brain J Neurol. 1982;105:189–21313.CrossRef
20.
Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995;32:959–67.CrossRef
21.
Hill ME, Richards MA, Gregory WM, Smith P, Rubens RD. Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer. 1993;68:969–73.CrossRef
22.
Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3:40–51.CrossRef
23.
Podd TJ, Carpenter DS, Baughan CA, Percival D, Dyson P. Spinal cord compression: prognosis and implications for treatment fractionation. Clin Oncol. 1992;4:341–4.CrossRef
Metadata
Title
A new and simple scoring system to predict overall survival after irradiation for metastatic spinal cord compression
Authors
P. Nenclares
S. Guardado
L. Asiáin
M. Á. Pérez-Escutia
M. C. Peña
A. Bartolomé
A. Ruíz
M. Á. Cabeza
M. Colmenero
N. Gascón
V. Rodríguez
R. Prados
R. D´Ambrosi
J. F. Pérez-Regadera
Publication date
01-03-2020
Publisher
Springer International Publishing
Keyword
Radiotherapy
Published in
Clinical and Translational Oncology / Issue 3/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02144-5

Other articles of this Issue 3/2020

Clinical and Translational Oncology 3/2020 Go to the issue

Research Article

Differences of the immune cell landscape between normal and tumor tissue in human prostate

Review Article

Altered expression and functional role of ion channels in leukemia: bench to bedside

Review Article

Circulating tumor cells in the clinical cancer diagnosis

Research Article

Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy

Research Article

Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21

Research Article

Coping strategies and depressive symptoms in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits